Generex Biotechnology Announces Appointment of New Independent Director
Integrated Development and Impact Management Services are independent consulting firms to the pharmaceuticals industry, providing informed guidance in operational, project and contract management, new business development and regulatory compliance. Ms. Allport-Settle has worked with companies such as GlaxoSmithKline, Pfizer, AstraZeneca, Johnson Controls and DSM Pharmaceuticals. She is currently working on her Masters Degree in Business Administration in Global Management at the University of Phoenix.
"We are very pleased that an individual with Mindy's extensive knowledge of and experience in the pharmaceuticals industry, particularly in the area of regulatory compliance, has agreed to join our board of directors," said Anna Gluskin, the President & Chief Executive Officer of Generex. "She is sure to make a valuable addition to the Company's board as we aggressively pursue the clinical and regulatory programs for Oralin(TM), our proprietary oral insulin spray formulation, and our other products."
Most read news
Topics
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.